Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

NCT05186818 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

282

Enrollment

INDUSTRY

Sponsor class

Conditions

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Interventions

DRUG: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg)
DRUG: Placebo to match aficamten

Sponsor

Cytokinetics

Collaborators

[object Object]